Home / Market News / $RXRX

$RXRX news and market catalysts

The 12 most recent market catalysts affecting $RXRX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

12 catalysts 3 high impact 4 bullish 3 bearish Biotechnology
Nov 18, 2026 Corporate Catalyst Neutral Impact 55
Morgan Stanley Maintains Hold Rating on Recursion Pharmaceuticals, Lowers Price Target
Morgan Stanley maintained its 'Hold' rating on Recursion Pharmaceuticals but significantly lowered its price target from an undisclosed previous value to $5.60. This move indicates…
Nov 18, 2026 Corporate Catalyst Bullish Impact 75
Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis
Recursion Pharmaceuticals has achieved a significant milestone by aligning with the FDA on the Phase 3 trial design for REC-4881, its drug for Familial Adenomatous Polyposis (FAP).…
Nov 13, 2026 Corporate Catalyst Neutral Impact 55
Bank of America Merrill Lynch Initiates Coverage on Recursion Pharmaceuticals
Bank of America Merrill Lynch's China healthcare team initiated coverage on Recursion Pharmaceuticals (RXRX), assigning a neutral rating and a $6.00 price target. This event is sig…
Nov 2, 2026 Corporate Catalyst Bullish Impact 75
Recursion Announces Positive Phase 2 Data for REC-4881 in TUPELO Trial
Recursion Pharmaceuticals reported positive Phase 2 data for REC-4881, an oral MEK1/2 inhibitor, in patients with familial adenomatous polyposis (FAP). The data showed deep and dur…
Nov 2, 2026 Corporate Catalyst Neutral Impact 75
Recursion Reports Third Quarter 2026 Financial Results and Business Updates
Recursion Pharmaceuticals announced its third-quarter 2026 financial results and provided updates on its clinical pipeline, specifically REC-4881 and REC-1245. This matters because…
Nov 2, 2026 Corporate Catalyst Neutral Impact 55
Recursion Appoints Fred Hassan as Chair of the Board
Recursion Pharmaceuticals has appointed Fred Hassan, a veteran of the pharmaceutical industry with extensive leadership experience at Schering-Plough and Pharmacia, as its new Boar…
Oct 29, 2026 Corporate Catalyst Neutral Impact 65
Recursion Pharmaceuticals Provides Pipeline Updates and Prepares for Q3 2026 Earnings
Recursion Pharmaceuticals announced an expansion of its Phase Ib/II TUPELO study for REC-4881, including broader age eligibility and an alternative dosing cohort. This move, couple…
Oct 16, 2026 Corporate Catalyst Bullish Impact 85
Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Know
Recursion Pharmaceuticals (RXRX) is raising $200 million through a stock offering, which typically dilutes existing shareholders but provides crucial capital for a clinical-stage b…
Oct 15, 2026 Corporate Catalyst Bullish Impact 85
Recursion Pharmaceuticals shares are trading higher after the company announced that Sanofi has optioned the first development candidate from the two companies’ multi-program research collaboration.
The headline signifies a major positive catalyst for Recursion Pharmaceuticals (RXRX). The optioning of a development candidate by a pharmaceutical giant like Sanofi validates Recu…
Aug 20, 2026 Corporate Catalyst Bearish Impact 65
Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why
The filing details two key events impacting the biotech sector. First, Recursion Pharmaceuticals (RXRX) is facing downward pressure due to a planned sale of 100,000 Class A shares …
Aug 5, 2026 Corporate Catalyst Bearish Impact 75
Recursion Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 financial results.
The headline directly points to a corporate catalyst: Recursion Pharmaceuticals (RXRX) reporting worse-than-expected Q2 financial results. This is a significant negative event for …
Aug 5, 2026 Corporate Catalyst Bearish Impact 92
Recursion Pharmaceuticals Q2 EPS $(0.25) Misses $(0.22) Estimate, Sales $7.670M Miss $11.947M Estimate
Recursion Pharmaceuticals (RXRX) announced Q2 earnings that fell short of analyst expectations on both the top and bottom lines. The reported loss of $(0.25) per share missed estim…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.